R 1454Alternative Names: R-1454
Latest Information Update: 16 Jul 2016
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in USA
- 31 Dec 2004 Phase-I clinical trials in Non-small cell lung cancer in USA (unspecified route)